Skip to main content

Table 1 Clinical significance of RUVBL2 staining in 153 HCC patients

From: Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma

  Nuclear RUVBL2 Cytoplasmic RUVBL2
Negative Weak Strong P value Negative Weak Strong P value
Age (year)     0.6548     0.3616
 < 60 55 (53.4) 32 (31.1) 16 (15.5)   4 (3.9) 42 (40.8) 57 (55.3)  
 ≥ 60 23 (46.0) 17 (34.0) 10 (20.0)   3 (6.0) 24 (48.0) 23 (46.0)  
Sex     0.6956     0.6332
 Male 74 (51.7) 44 (30.8) 25 (17.5)   7 (4.9) 60 (42.0) 76 (53.1)  
 Female 4 (40.0) 5 (50.0) 1 (10.0)   0 (0.0) 6 (60.0) 4 (40.0)  
Family history     0.3719     0.4666
 Yes 56 (52.8) 35 (33.0) 15 (14.2)   3 (2.8) 45 (42.5) 58 (54.7)  
 No 22 (46.8) 14 (29.8) 11 (23.4)   4 (8.5) 21 (44.7) 22 (46.8)  
Symptomatic presentation     0.1776     0.9539
 No 54 (56.8) 27 (28.4) 14 (14.7)   7 (7.4) 39 (41.1) 49 (51.6)  
 Yes 24 (41.4) 22 (37.9) 12 (20.7)   0 (0.0) 27 (46.6) 31 (53.4)  
Drinking     0.0316     0.3927
 No 59 (52.7) 30 (26.8) 23 (20.5)   5 (4.5) 52 (46.4) 55 (49.1)  
 Infrequent 17 (47.2) 16 (44.4) 3 (8.3)   2 (5.6) 11 (30.6) 23 (63.9)  
 Frequent 2 (40.0) 3 (60.0) 0 (0.0)   0 (0.0) 3 (60.0) 2 (40.0)  
HBsAg     0.1774     0.3722
 Negative 12 (42.9) 13 (46.4) 3 (10.7)   0 (0.0) 14 (50.0) 14 (50.0)  
 Positive 66 (52.8) 36 (28.8) 23 (18.4)   7 (5.6) 52 (41.6) 66 (52.8)  
Anti-HCV     0.9411     0.4514
 Negative 72 (51.4) 44 (31.4) 24 (17.1)   7 (5.0) 58 (41.4) 75 (53.6)  
 Positive 6 (46.2) 5 (38.5) 2 (15.4)   0 (0.0) 8 (61.5) 5 (38.5)  
Cirrhosis     0.0416     0.2321
 w/o + mild 33 (41.3) 33 (41.3) 14 (17.5)   3 (3.8) 31 (38.8) 46 (57.5)  
 Moderate 23 (62.2) 7 (18.9) 7 (18.9)   3 (8.1) 19 (51.4) 15 (40.5)  
 Severe 22 (61.1) 9 (25.0) 5 (13.9)   1 (2.8) 16 (44.4) 19 (52.8)  
CEA (ng/ml)     0.8181     0.8920
 ≤ 5 72 (51.1) 48 (34.0) 21 (14.9)   5 (3.5) 63 (44.7) 73 (51.8)  
 > 5 6 (50.0) 1 (8.3) 5 (41.7)   2 (16.7) 3 (25.0) 7 (58.3)  
ALP     0.8388     0.9196
 Normal 71 (51.1) 46 (33.1) 22 (15.8)   5 (3.6) 61 (43.9) 73 (52.5)  
 Aberrant 7 (50.0) 3 (21.4) 4 (28.6)   2 (14.3) 5 (35.7) 7 (50.0)  
PT(a) (%)     0.4977     0.2135
 ≥ 80 51 (54.3) 26 (27.7) 17 (18.1)   4 (4.3) 36 (38.3) 54 (57.4)  
 < 80 27 (47.4) 21 (36.8) 9 (15.8)   3 (5.6) 28 (30.6) 26 (63.9)  
AFP (ng/ml)     0.2972     0.1644
 ≤ 20 33 (44.0) 26 (34.7) 16 (21.3)   4 (5.3) 27 (36.0) 44 (58.7)  
 > 20 41 (55.4) 23 (31.1) 10 (13.5)   3 (4.1) 37 (50.0) 34 (45.9)  
AFP (ng/ml)     0.7712     0.5453
 ≤ 400 57 (51.4) 35 (31.5) 19 (17.1)   5 (4.5) 50 (45.0) 56 (50.5)  
 > 400 17 (44.7) 14 (36.8) 7 (18.4)   2 (5.3) 14 (36.8) 22 (57.9)  
Differentiation grade     0.5340     0.0016
 Well 15 (57.7) 8 (30.8) 3 (11.5)   5 (19.2) 14 (53.8) 7 (26.9)  
 Moderate 48 (51.6) 31 (33.3) 14 (15.1)   1 (1.1) 44 (47.3) 48 (51.6)  
 Poor 15 (44.1) 10 (29.4) 9 (26.5)   1 (2.9) 8 (23.5) 25 (73.5)  
Tumor size (cm)     0.6152     0.6543
 ≤ 5 53 (52.5) 33 (32.7) 15 (14.9)   6 (5.9) 44 (43.6) 51 (50.5)  
 > 5 25 (48.1) 16 (30.8) 11 (21.2)   1 (1.9) 22 (42.3) 29 (55.8)  
Multinodules     0.9897     0.9068
 No 62 (50.8) 39 (32.0) 21 (17.2)   5 (4.1) 54 (44.3) 63 (51.6)  
 Yes 16 (51.6) 10 (32.3) 5 (16.1)   2 (6.5) 12 (38.7) 17 (54.8)  
Tumor-infiltrating lymphocytes     0.6644     0.8294
 No 57 (50.4) 35 (31.1) 21 (18.6)   6 (5.3) 49 (43.4) 58 (51.3)  
 Yes 21 (52.5) 14 (35.0) 5 (20.7)   1 (2.5) 17 (42.5) 22 (55.0)  
Liver capsule invasion     0.7086     0.7920
 No 48 (52.7) 27 (29.7) 16 (17.6)   5 (5.5) 40 (44.0) 46 (50.5)  
 Yes 29 (47.5) 22 (36.1) 10 (16.4)   2 (3.3) 26 (42.6) 33 (54.1)  
Carcinoma cell embolus     0.3656     0.1208
 No 66 (48.9) 45 (33.3) 24 (17.8)   7 (5.2) 61 (45.2) 67 (49.6)  
 Yes 12 (66.7) 4 (22.2) 2 (11.1)   0 (0.0) 5 (27.8) 13 (72.2)  
TNM staging     0.6785     0.8315
 I 55 (49.1) 36 (32.1) 21 (18.8)   4 (3.6) 51 (45.5) 57 (50.9)  
 II 11 (52.4) 8 (38.1) 2 (9.5)   2 (9.5) 9 (42.9) 10 (47.6)  
 III 9 (56.3) 4 (25.0) 3 (18.8)   0 (0.0) 6 (37.5) 10 (62.5)  
 IV 3 (75.0) 1 (25.0) 0 (0.0)   1 (25.0) 0 (0.0) 3 (75.0)  
BCLC staging     0.4584     0.3621
 0 4 (66.7) 0 (0.0) 2 (33.3)   0 (0.0) 3 (50.0) 3 (50.0)  
 1 57 (47.9) 41 (34.5) 21 (17.6)   7 (5.9) 53 (44.5) 59 (49.6)  
 2 12 (54.5) 7 (31.8) 3 (13.6)   0 (0.0) 8 (36.4) 14 (63.6)  
 3 5 (83.3) 1 (16.7) 0 (0.0)   0 (0.0) 2 (33.3) 4 (66.7)